TY - JOUR
T1 - The Association Between Lung Hyperinflation and Coronary Artery Disease in Smokers
AU - COPDGene Investigators
AU - Chandra, Divay
AU - Gupta, Aman
AU - Kinney, Gregory L.
AU - Fuhrman, Carl R.
AU - Leader, Joseph K.
AU - Diaz, Alejandro A.
AU - Bon, Jessica
AU - Barr, R. Graham
AU - Washko, George
AU - Budoff, Matthew
AU - Hokanson, John
AU - Sciurba, Frank C.
AU - Crapo, James D.
AU - Silverman, Edwin K.
AU - Make, Barry J.
AU - Regan, Elizabeth A.
AU - Beaty, Terri
AU - Begum, Ferdouse
AU - Boueiz, Adel R.
AU - Castaldi, Peter J.
AU - Cho, Michael
AU - DeMeo, Dawn L.
AU - Foreman, Marilyn G.
AU - Halper-Stromberg, Eitan
AU - Hayden, Lystra P.
AU - Hersh, Craig P.
AU - Hetmanski, Jacqueline
AU - Hobbs, Brian D.
AU - Hokanson, John E.
AU - Laird, Nan
AU - Lange, Christoph
AU - Lutz, Sharon M.
AU - McDonald, Merry Lynn
AU - Parker, Margaret M.
AU - Prokopenko, Dmitry
AU - Qiao, Dandi
AU - Sakornsakolpat, Phuwanat
AU - Wan, Emily S.
AU - Won, Sungho
AU - Al Qaisi, Mustafa
AU - Coxson, Harvey O.
AU - Gray, Teresa
AU - Han, Mei Lan K.
AU - Hoffman, Eric A.
AU - Humphries, Stephen
AU - Jacobson, Francine L.
AU - Judy, Philip F.
AU - Kazerooni, Ella A.
AU - Anzueto, Antonio
AU - Maselli-Caceres, Diego
N1 - Publisher Copyright:
© 2021
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Background: Smokers manifest varied phenotypes of pulmonary impairment. Research Question: Which pulmonary phenotypes are associated with coronary artery disease (CAD) in smokers? Study Design and Methods: We analyzed data from the University of Pittsburgh COPD Specialized Center for Clinically Oriented Research (SCCOR) cohort (n = 481) and the Genetic Epidemiology of COPD (COPDGene) cohort (n = 2,580). Participants were current and former smokers with > 10 pack-years of tobacco exposure. Data from the two cohorts were analyzed separately because of methodologic differences. Lung hyperinflation was assessed by plethysmography in the SCCOR cohort and by inspiratory and expiratory CT scan lung volumes in the COPDGene cohort. Subclinical CAD was assessed as the coronary artery calcium score, whereas clinical CAD was defined as a self-reported history of CAD or myocardial infarction (MI). Analyses were performed in all smokers and then repeated in those with airflow obstruction (FEV1 to FVC ratio, < 0.70). Results: Pulmonary phenotypes, including airflow limitation, emphysema, lung hyperinflation, diffusion capacity, and radiographic measures of airway remodeling, showed weak to moderate correlations (r < 0.7) with each other. In multivariate models adjusted for pulmonary phenotypes and CAD risk factors, lung hyperinflation was the only phenotype associated with calcium score, history of clinical CAD, or history of MI (per 0.2 higher expiratory and inspiratory CT scan lung volume; coronary calcium: OR, 1.2; 95% CI, 1.1-1.5; P = .02; clinical CAD: OR, 1.6; 95% CI, 1.1-2.3; P = .01; and MI in COPDGene: OR, 1.7; 95% CI, 1.0-2.8; P = .05). FEV1 and emphysema were associated with increased risk of CAD (P < .05) in models adjusted for CAD risk factors; however, these associations were attenuated on adjusting for lung hyperinflation. Results were the same in those with airflow obstruction and were present in both cohorts. Interpretation: Lung hyperinflation is associated strongly with clinical and subclinical CAD in smokers, including those with airflow obstruction. After lung hyperinflation was accounted for, FEV1 and emphysema no longer were associated with CAD. Subsequent studies should consider measuring lung hyperinflation and examining its mechanistic role in CAD in current and former smokers.
AB - Background: Smokers manifest varied phenotypes of pulmonary impairment. Research Question: Which pulmonary phenotypes are associated with coronary artery disease (CAD) in smokers? Study Design and Methods: We analyzed data from the University of Pittsburgh COPD Specialized Center for Clinically Oriented Research (SCCOR) cohort (n = 481) and the Genetic Epidemiology of COPD (COPDGene) cohort (n = 2,580). Participants were current and former smokers with > 10 pack-years of tobacco exposure. Data from the two cohorts were analyzed separately because of methodologic differences. Lung hyperinflation was assessed by plethysmography in the SCCOR cohort and by inspiratory and expiratory CT scan lung volumes in the COPDGene cohort. Subclinical CAD was assessed as the coronary artery calcium score, whereas clinical CAD was defined as a self-reported history of CAD or myocardial infarction (MI). Analyses were performed in all smokers and then repeated in those with airflow obstruction (FEV1 to FVC ratio, < 0.70). Results: Pulmonary phenotypes, including airflow limitation, emphysema, lung hyperinflation, diffusion capacity, and radiographic measures of airway remodeling, showed weak to moderate correlations (r < 0.7) with each other. In multivariate models adjusted for pulmonary phenotypes and CAD risk factors, lung hyperinflation was the only phenotype associated with calcium score, history of clinical CAD, or history of MI (per 0.2 higher expiratory and inspiratory CT scan lung volume; coronary calcium: OR, 1.2; 95% CI, 1.1-1.5; P = .02; clinical CAD: OR, 1.6; 95% CI, 1.1-2.3; P = .01; and MI in COPDGene: OR, 1.7; 95% CI, 1.0-2.8; P = .05). FEV1 and emphysema were associated with increased risk of CAD (P < .05) in models adjusted for CAD risk factors; however, these associations were attenuated on adjusting for lung hyperinflation. Results were the same in those with airflow obstruction and were present in both cohorts. Interpretation: Lung hyperinflation is associated strongly with clinical and subclinical CAD in smokers, including those with airflow obstruction. After lung hyperinflation was accounted for, FEV1 and emphysema no longer were associated with CAD. Subsequent studies should consider measuring lung hyperinflation and examining its mechanistic role in CAD in current and former smokers.
KW - COPD
KW - coronary artery disease
KW - lung hyperinflation
KW - smoking
UR - https://www.scopus.com/pages/publications/85113560600
UR - https://www.scopus.com/pages/publications/85113560600#tab=citedBy
U2 - 10.1016/j.chest.2021.04.066
DO - 10.1016/j.chest.2021.04.066
M3 - Article
C2 - 33971144
AN - SCOPUS:85113560600
SN - 0012-3692
VL - 160
SP - 858
EP - 871
JO - Chest
JF - Chest
IS - 3
ER -